JANUARY 25-27 2018 MARRIOTT RIVE GAUCHE & CONFERENCE CENTER PARIS, FRANCE WWW.CACVS.ORG

# Brachial Vein AVF: Where are we

Lamisse KARAM,MD – MSc. Beirut - Lebanon

# AP

### Disclosure

Lamisse KARAM

- I have the following potential conflicts of interest to report:
- Consulting
- Employment in industry
- Shareholder in a healthcare company
- Owner of a healthcare company
- Other(s)
- I do not have any potential conflict of interest





2006 Updates Clinical Practice Guidelines and Recommendations

Hemodialysis Adequacy
Peritoneal Dialysis Adequacy

Vascular Access

Full Text of Guidelines and Recommendations

The Society for Vascular Surgery: Clinical practice guidelines for the surgical placement and maintenance of arteriovenous hemodialysis access

We recommend optimizing the placement of autogenous accesses using the following *operative* strategies:

- A. AV accesses AS FAR DISTALLY e upper extremity as possible to preserve proximal sites for future accesses (GRADE 1 recommendation, very low-quality evidence).
- B. When possibl AUTOGENOUS should be considered before products are consumed accesses are placed. These autogenous access configurations should include, in order of preference, the use of direct AV anastomosis, venous transpositions, and translocations (GRADE 1 recommendation, very low-quality evidence).
- C. Upper extremity access sites are used first, with the nondominant arm given preference over the dominant arm only when access opportunities are equal in both extremities (GRADE 1 recommendation, very low-quality evidence).
- D. Lower extremity and body wall access sites are used only after all upper extremity access sites have been exhausted (GRADE 1 recommendation, very lowquality evidence).

### JVS 2008







JANUARY 25-27 2018 MARRIOTT RIVE GAUCHE & CONFERENCE CENTER PARIS, FRANCE WWW.CACVS.ORG





vascular access planning. J Vasc Surg 2011;53:720-4.





# CONTROVERSIES & UPDATES

JANUARY 25-27 2018 MARRIOTT RIVE GAUCHE & CONFERENCE CENTER PARIS, FRANCE WWW.CACVS.ORG







#### BOURGERY et JACOB, Paris – 1840.



































Schanzer	2004	2	Primary	Restrospective review
Angle	2005	20	staged	Restrospective review
Dorobantu	2006	33	staged	Restrospective review
Elwakeel	2007	21	staged	Restrospective review
Stembengh	2008	17	primary	Restrospective review: basilic vs brachial VT
Angle	2008	42	Often staged	Restrospective review : BVT vs AVG
jennings	2008	6	staged	Restrospective review: basilic and brachial VT
Schanzer	2008	13	11 vs 2	Restrospective review: brachial VT vs AVG vs basilic VT
Casey	2008	17	primary	Restrospective review: brachial vs basilic VT
Torina	2008	13	11 vs 2	Restrospective review: brachial VT vs AVG vs basilic VT
Jennings	2009	58	13 vs 45	Retrospective
Lioupis	2011	15	N/A	Retrospective review: Brachial VT, basilic VT and flixene graft
Lambidis	2013	1	primary	Case report
Pham	2017	29	staged	Retrospective review, BVT vs AVG
Karam	2018	64	63 staged	Retrospective review

Schanzer	2004	2	Primary	Restrospective review
Angle	2005	20	staged	Restrospective review
Dorobantu	2006	33	staged	Restrospective review
Elwakeel	2007	21	staged	Restrospective review
Stembengh	2008	17	primary	Restrospective review: basilic vs brachial VT
Angle	2008	42	Often staged	Restrospective review : BVT vs AVG
jennings	2008	6	staged	Restrospective review: basilic and brachial VT
Schanzer	2008	13	11 vs 2	Restrospective review: brachial VT vs AVG vs basilic VT
Casey	2008	17	primary	Restrospective review: brachial vs basilic VT
Torina	2008	13	11 vs 2	Restrospective review: brachial VT vs AVG vs basilic VT
Jennings	2009	58	13 vs 45	Retrospective
Lioupis	2011	15	N/A	Retrospective review: Brachial VT, basilic VT and flixene graft
Lambidis	2013	1	primary	Case report
Pham	2017	29	staged	Retrospective review, BVT vs AVG
Karam	2018	64	63 staged	Retrospective review

Schanzer	2004	2	Primary	Restrospective review
Angle	2005	20	staged	Restrospective review
Dorobantu	2006	33	staged	Restrospective review
Elwakeel	2007	21	staged	Restrospective review
Stembengh	2008	17	primary	Restrospective review: basilic vs brachial VT
Angle	2008	42	Often staged	Restrospective review : BVT vs AVG
Jennings	2008	6	staged	Restrospective review: basilic and brachial VT
Schanzer	2008	13	11 vs 2	Restrospective review: brachial VT vs AVG vs basilic VT
Casey	2008	17	primary	Restrospective review: brachial vs basilic VT
Torina	2008	13	11 vs 2	Restrospective review: brachial VT vs AVG vs basilic VT
Jennings	2009	58	13 vs 45	Retrospective
Lioupis	2011	15	N/A	Retrospective review: Brachial VT, basilic VT and flixene graft
Lambidis	2013	1	primary	Case report
Pham	2017	29	staged	Retrospective review, BVT vs AVG
Karam	2018	64	63 staged	Retrospective review

Schanzer	2004	2	Primary	Restrospective review
Angle	2005	20	staged	Restrospective review
Dorabantu	2006	33	staged	Restrospective review
Elwakeel	2007	21	staged	Restrospective review
Stembeng	2008	42	primary	Restrospective review: basilic vs brachial VT
Angle	2008	42	Often staged	Restrospective review : BVT vs AVG
jennings	2008	6	staged	Restrospective review: basilic and brachial VT
Schanzer	2008	13	11 vs 2	Restrospective review: brachial VT vs AVG vs basilic VT
Casey	2008	17	primary	Restrospective review: brachial vs basilic VT
Torina	2008	13	11 vs 2	Restrospective review: brachial VT vs AVG vs basilic VT
Jennings	2009	<b>58</b>	13 vs 45	Retrospective
Lioupis	2011	15	N/A	Retrospective review: Brachial VT, basilic VT and flixene graft
Lambidis	2013	1	primary	Case report
Pham	2017	29	staged	Retrospective review, BVT vs AVG
Karam	2018	<b>64</b>	63 staged	Retrospective review

Schanzer	2004	2	Primary	Restrospective review
Angle	2005	20	staged	Restrospective review
Dorobantu	2006	33	staged	Restrospective review
Elwakeel	2007	21	staged	Restrospective review
Stembengh	2008	17	primary	Restrospective review: basilic vs brachial VT
Angle	2008	42	Often staged	Restrospective review : BVT vs AVG
jennings	2008	6	staged	Restrospective review: basilic and brachial VT
Schanzer	2008	13	11 vs 2	Restrospective review: brachial VT vs AVG vs basilic VT
Casey	2008	17	primary	Restrospective review: brachial vs basilic VT
Torina	2008	13	11 vs 2	Restrospective review: brachial VT vs AVG vs basilic VT
Jennings	2009	58	13 vs 45	Retrospective
Lioupis	2011	15	N/A	Retrospective review: Brachial VT, basilic VT and flixene graft
Lambidis	2013	1	primary	Case report
Pham	2017	29	staged	Retrospective review, BVT vs AVG
Karam	2018	64	63 staged	Retrospective review

#### AUTHOR YEAR No 1vs2 STAGES OUTCOMES

Schanzer	2004	2	Primary	Both successful at 12 months
Angle	2005	20	staged	85% overall patency at 14 months
Dorabantu	2006	33	staged	85% overall patency at 3-26 months
Elwakeel	2007	21	staged	75.9% cumulative patency at 1 year
Stembeng	2008	42	primary	40% functionnal at 1year comparable to basilic VT patency
Angle	2008	42	Often staged	BVT > prosthetic grafts in early referral patient, BVT patency not reported separately
jennings	2008	6	staged	4 of 6 BVTs successful; BVT patency not reported separately
Schanzer	2008	13	11 vs 2	Higher complication rate and lower patency rate for primary BVT
Casey	2008	17	primary	Comparable patency rates at 12 months
Torina	2008	13	11 vs 2	45.7% functional patency rates at 12 months
Jennings	2009	<b>58</b>	13 vs 45	92.4% cumulative patency at 1 and 2 years
Lioupis	2011	15	N/A	Basilic VT :Lower reintervention BVT: lower functional patency rate (18 m)
Lambidis	2013	1	primary	Patent at 10 months
Pham	2017	29	staged	62% 1year primary patency
Karam	2018	64	63 staged	60% 1 year secondary patency 91% 1-year secondary functional patency



## Brachial vein transposition is a promising ultimate upper limb autologous arteriovenous angioaccess despite its many pitfalls

Lamisse Karam, MD. Marek Rawa, MD. Richard Shoenfeld, MD, and Pierre Bourquelot, MD.



4 years were 50% (±7%), 42% (±7%), 7% (±8%), and 27% (±1%), respectively. Primary assisted patency rates (±S) at 1 year, 2 years, 3 years, and 4 years were 60% (±6%), 51% (±7%), respectively. Primary assisted patency rates (±S) at 1 year, 2 years, 3 years, and 4 years were 60% (±6%), 51% (±7%), 45% (±7%), and 37% (±9%), respectively. Secondary patency rates (±SD) at 1 year, 2 years, 3 years, and 4 years were 60% (±6%), 53% (±7%), 53% (±7%), and 45% (±8%), respectively. Early complications included thrombosis, nonmaturation, and upper arm edema. At the second stage (n = 50), four patients presented with unexplained major fibrosis extending cephalad from the first surgical site and preventing any dissection of the vein. Four patients had more usual complications (one nonmaturation, two occlusions of the brachial vein at the previous arteriovenous graft-vein anastomosis), and two were lost to follow-up. Vein transposition in a subcutaneous tunnel was technically unfeasible in eight patients. Of the 64 patients, 40 (62%) had a functional BrVT that was cannulated for effective dialysis after a median interval of 72 days (15-420 days) from the first stage. Mean cumulative secondary patency rates (from first cannulation) at 1 year. 2 years, and 3 years were 90% ± 5%. 72% ± 5% and

### J Vasc Surg 2018;67:236-43

Chronic kidney disease is a major public neatm problem worldwide. Since 2006, National Kidney Foundation Kidney Disease Outcomes Quality Initiative guidelines (currently being revised) have tried to present a structured approach to the choice of type and location of long-term angioaccess for hemodialysis and for treatment of sickle cell disease to minimize complications

From the Vascular Surgery Department, Notre Dame de Secours Hospital, Byblos<sup>6</sup>, Polyclinique Zerhoun, ex Polyclinique Cornette de Saint Cyr, Meknes<sup>6</sup>, The Access Center, West Orange<sup>6</sup>; and the Department of Angloaccess Surgery, Clinique Jouvenet, Paris.<sup>4</sup>

Author conflict of interest: none.

Presented at the Vascular Access Session of the Controversies and Updates in Vascular Surgery Eleventh Annual Meeting. Paris, France, January 22:24, 2015. Correspondence: Pierre Bourquelot, MD. Department of Angioaccess Surgery, Clinique Jouvenet, 6 Square Jouvenet, Paris 75016, France (e-mail: pierre@

bourquelot/r). The editors and reviewers of this article have no relevant financial relationships to disclose per the JVS policy that requires reviewers to decline review of any manuscript for which they may have a conflict of interest.

0741-5214

Copyright © 2017 by the Society for Vascular Surgery. Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jvs.2017.05.120 and to optimize access survival: An autologous arteriovenous fistula (AVF) is the preferred long-term access because of its lower rate of complications and longer survival of both the access and the patient.<sup>13</sup> Prosthetic grafts should be considered only in the absence of a suitable vein. One way of extending the availability of an autologous vein is to consider one of the two brachial veins as a plausible choice in the absence of other possibilities in the upper extremities.<sup>46</sup> We report our experience using this vein for brachial vein transposition (BrVT) in terms of maturation, patency, and complications.

#### METHODS

New BrVT access was created for hemodialysis in 54 patients, blood exchange or transfusion in 9 patients, and long-term parenteral nutrition in 1 patient. Candidates referred for vascular access were considered for BrVT when no other upper extremity autologous vascular access was possible. Characteristics of the patients are listed in the Table.



- 64 patients
- Preoperative vein mapping by venography or color duplex ultrasound
- two stages in all patients but one.
- Ultrasound-guided local-regional anesthesia and no-touch surgical technique without vein infusion or distention







JANUARY 25-27 2018 MARRIOTT RIVE GAUCHE & CONFERENCE CENTER PARIS, FRANCE WWW.CACVS.ORG





Standardization of selection criteria Standardization of duplex ultrasound imaging criteria

JANUARY 25-27 2018 MARRIOTT RIVE GAUCHE & CONFERENCE CENTER PARIS, FRANCE WWW.CACVS.ORG





Lamisse.karam@gmail.com